From the Editor

Sep 06, 2017
Pharmaceutical Executive
A big thank you to you, our readers, for lending your voice to Pharm Exec's editorial mission—giving you the information you need and want. Click ahead for a look at some of the future topics we'll be tackling.
Aug 07, 2017
Pharmaceutical Executive
As more states approve the use of medical marijuana—and its rising profile as potential opioid alternative—industry and FDA are stepping up their focus on developing cannabis-derived therapies.
Jul 07, 2017
Pharmaceutical Executive
As we step further into the waters of value-based contracting arrangements, lessons learned must be shared—including the role of the patient in the equation.
Jun 09, 2017
Pharmaceutical Executive
There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine, writes Lisa Henderson.
May 04, 2017
Pharmaceutical Executive
Recent PR disasters in other industries raise an important reputational question that can apply to pharma as well: do you want to be someone that works the system or improves the system?
Apr 06, 2017
Pharmaceutical Executive
Two topics in Pharm Exec this month—rare disease research and women in healthcare leadership—share a "common" thread.
Mar 09, 2017
Pharmaceutical Executive
No longer just hype, investing in big data is the path to the future for pharma, even if big returns aren't a direct result, writes Pharm Exec Editor Lisa Henderson.
Feb 08, 2017
Pharmaceutical Executive
Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.
Dec 09, 2016
Pharmaceutical Executive
Despite industry's success in translating discovery research into products with proven clinical value, it continues to struggle in positioning medical research to the public as a distinctive force for good, writes William Looney.
Nov 07, 2016
Pharmaceutical Executive
The influx of treatment breakthroughs and expanding science has not silenced the debate over the productivity of biopharma's R&D model, and the looming challenges for R&D decision-makers.
native1_300x100
lorem ipsum